New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.96 2.22 +1.67%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. (MRK) news

The news and the share price important stories, numbered as below

Share price since Oct 21 −10.0%

Stories the last two months, newest first

  1. Legal ·

    German court overturns injunction blocking Merck’s Keytruda SC

    A German Higher Regional Court overturned a preliminary injunction that had barred Merck from offering or distributing Keytruda SC in Germany. Halozyme plans to file a patent infringement lawsuit seeking permanent relief. The German proceedings are separate from a Dutch ruling that restricts Keytruda SC in eight European countries, which remains in effect.

    Reported by 2: Stocktwits · Zacks

  2. Deal ·

    Merck and Isomorphic Labs partner on AI-designed oncology drug candidates

    Merck and Isomorphic Labs will collaborate to design small-molecule candidates for an oncology target, combining Isomorphic’s AI drug-design engine with Merck’s proprietary data and discovery expertise. Isomorphic will receive an upfront payment, milestone payments and tiered royalties, with an option to co-fund development for higher royalties. Merck will handle preclinical and clinical development, manufacturing and commercialization.

    Reported by 3: Business Wire · InvestorsHub · pharmaceutical-technology.com

  3. Commentary ·

    Merck evaluates personalized cancer vaccine beyond melanoma

    Merck is evaluating whether its personalized cancer vaccine can work beyond melanoma, with kidney cancer data from a low-TMB population expected to clarify the roles of mutation burden, KEYTRUDA responsiveness, HLA and the tumor environment. No efficacy results are available yet, and melanoma responses may take time to emerge. The vaccine is also being tested alone and with BCG for early-stage bladder cancer.

    Reported by MarketBeat

  4. Other ·

    Merck discontinues nemtabrutinib and the Phase 3 BELLWAVE program

    Merck is discontinuing the Phase 3 BELLWAVE-011 trial and the broader nemtabrutinib development program, including BELLWAVE-008 and BELLWAVE-010, after safety-benefit reviews suggested the risks may outweigh benefits. The decision removes a late-stage blood cancer candidate from Merck’s pipeline. Trial analyses are ongoing, with results to be shared with the scientific community.

    Reported by 3: Business Wire · Zacks · Simply Wall St

  5. Commentary ·

    Merck expects moderate 2027 growth amid generic competition

    Keytruda, newer medicines Winrevair and Welireg, and Animal Health are driving growth. New products and pipeline progress may help offset Keytruda’s 2028 patent expiry, but Gardasil challenges, competition, and generic erosion—including for Bridion and Januvia—remain risks. Merck expects moderate revenue growth in 2027.

    Reported by Zacks

  6. Analyst ·

    Goldman Sachs raises Merck price target to $165

    Goldman Sachs raised its Merck price target to $165 from $155 and maintained a Buy rating, putting it near the $162 analyst consensus and 14% above the Nov. 16 close. Analysts’ 2027 EPS consensus has fallen to $8.96, roughly matching 2025 earnings, amid more than $2 billion in expected generic-drug headwinds. Keytruda’s U.S. patent expiry in 2028 and Medicare price reductions from 2029 heighten the importance of pipeline products.

    Reported by TIKR

  7. Capital ·

    Merck advances pipeline while declaring a $0.88 quarterly dividend

    Merck reported positive CHMP opinions for expanded ENFLONSIA and WELIREG indications and Phase 2b results for efinopegdutide in MASH, advancing efforts to diversify beyond KEYTRUDA. The developments support its respiratory, oncology and liver-disease pipeline but are not yet transformative financial drivers. KEYTRUDA erosion, pipeline setbacks, debt and execution on 2027 guidance remain key risks.

    Reported by Simply Wall St

  8. Commentary ·

    Merck’s Gardasil sales may face a 2027 reversal

    In fiscal Q3 2026, Gardasil generated $2 billion, more than newer launches, while WINREVAIR and KEYTRUDA QLEX grew rapidly. Gardasil’s 14% sales increase may largely reflect temporary vaccine-purchase timing, with $250 million of that benefit expected to unwind in 2027. Merck forecasts moderate top-line growth from new products and animal health, partly offset by more than $2 billion in generic competition.

    Reported by Trefis

  9. Commentary ·

    Merck shares trade near $150 as Keytruda patent risks remain

    Keytruda generated $8.6 billion in third-quarter revenue, including $830 million from Qlex, and accounted for nearly half of Merck’s revenue. Generic competition is still expected to reduce sales, leaving uncertainty about the size of the decline. At a forward P/E of 16, Merck trades below the S&P 500’s multiple of under 19, but the valuation discount may not adequately compensate for the risk.

    Reported by The Motley Fool

  10. Other ·

    Merck receives EU recommendations for Welireg combination and Enflonsia expansion

    The European Medicines Agency’s CHMP recommended expanding ENFLONSIA’s EU indication to prevent RSV lower respiratory tract disease in vulnerable children up to 24 months old through their second RSV season. It also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cancer after anti-PD-1/PD-L1 treatment. The European Commission is expected to decide on both recommendations within two months.

    Reported by 4: Business Wire · Business Wire · MT Newswires · Simply Wall St.

  11. 1 Results ·

    Merck reports third-quarter sales of $18.1 billion and raises 2026 guidance

    Third-quarter 2026 sales rose 5% to $18.1 billion. Keytruda and Keytruda Qlex sales increased 6% to $8.6 billion, while Winrevair sales climbed 93% to $694 million. Merck raised its full-year revenue guidance after third-quarter revenue and adjusted EPS exceeded expectations, though net income fell to $5.065 billion.

    Reported by 4: Zacks · Investing.com · Insider Monkey · Simply Wall St.

  12. Other ·

    Merck reports positive Phase 2b efinopegdutide results in MASH

    At 52 weeks, MASH resolution without worsening fibrosis occurred in 56%, 63% and 61% of participants taking 4 mg, 7 mg and 10 mg, respectively, versus 13% on placebo; all results were statistically significant. Efinopegdutide remains investigational and has FDA Fast Track designation. Side effects were generally consistent with semaglutide, though adverse-event discontinuations reached 11% at the highest dose.

    Reported by 2: Business Wire · Simply Wall St.

  13. Commentary ·

    Merck faces uncertainty over growth and margins

    Merck shares gained 78.5% over the past year and trade near a ten-year high valuation relative to sales, despite weak trailing earnings and a recent margin recovery that has lasted only one quarter. The company’s 2026 sales guidance is slightly below its trailing-year revenue, while analysts expect a stronger fourth quarter than guidance implies. Investors face uncertainty over whether sales and margins can meet market expectations.

    Reported by Trefis

  14. Other ·

    Merck starts Phase 3 OHTUVAYRE COPD trial as FDA reviews cancer drug

    Merck has launched the ENHANCE-3 Phase 3 trial of OHTUVAYRE as a COPD maintenance treatment. The drug was recently approved in the U.S. as the first new inhaled COPD maintenance option in more than 20 years with both bronchodilatory and anti-inflammatory action. The FDA also granted priority review to Merck’s sacituzumab tirumotecan for endometrial cancer.

    Reported by Simply Wall St.

  15. Commentary ·

    Merck valuation debate weighs cash flow against Keytruda transition risks

    Merck’s latest 12-month free cash flow is about $14.8 billion, with Simply Wall St’s DCF model projecting it to exceed $24 billion annually by 2030 and valuing the shares above their cited $146.73 price. Positive cancer-trial data and a broad pipeline support the cash-flow outlook, while analyst narratives differ: one sees the stock as 8% undervalued, another as 19% overvalued.

    Reported by Simply Wall St.

  16. Commentary ·

    Merck faces generic headwinds and moderating Keytruda growth

    Keytruda accounts for over 55% of pharmaceutical sales and faces biosimilar competition around its 2028 patent expiry. Gardasil weakness, more than $2 billion in expected 2027 generic headwinds, and moderating Keytruda growth are expected to limit near-term revenue growth. Acquisitions and a promising pipeline could help offset the patent cliff, with Merck projecting over $70 billion in potential pipeline revenue by the mid-2030s.

    Reported by Zacks

  17. Commentary ·

    Baron Health Care Fund adds to its Merck holding

    Baron Health Care Fund added to Merck in Q3 2026, citing the company’s business development and pipeline investment to prepare for Keytruda’s anticipated loss of exclusivity. The fund returned 4.02% during the quarter, trailing its benchmark. Merck shares had gained 74.08% over the prior 52 weeks as of November 4, 2026.

    Reported by Insider Monkey

  18. Deal ·

    Merck agrees to sell its CDMO business to Lonza

    Merck agreed to sell its CDMO business to Lonza for a mid-triple-digit million-euro amount, with closing expected in mid-2027 pending approvals. The sale includes U.S. facilities in California, Wisconsin, Missouri and Indiana. Merck will retain BioReliance Contract Testing Services and continue supplying customers with consumables, technologies and services during the transition.

    Reported by GlobeNewswire

  19. Analyst ·

    Cantor Fitzgerald raises Merck price target to $155

    Merck shares fell 1.24% to $147.66 despite Cantor Fitzgerald raising its price target to $155 from $145 and maintaining a Neutral rating. Winrevair sales rose 93% to $694 million, but remained about 3.8% of Merck’s $18.1 billion quarterly revenue, compared with $8.6 billion from Keytruda. The article said sustained dollar gains are needed for Winrevair to materially affect the business.

    Reported by GuruFocus.com

  20. Other ·

    Merck plans HIV pipeline presentations as FDA reviews IDVYNSO applications

    Merck plans to present HIV treatment and prevention pipeline data at HIV Glasgow 2026, including analyses for daily IDVYNSO and investigational weekly regimens. The company also plans updates on other weekly and monthly candidates. The FDA accepted two supplemental applications for IDVYNSO, with an April 22, 2027 target action date.

    Reported by 2: Business Wire · Simply Wall St.

More headlines